Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Indaptus Therapeutics Inc INDP

Healthcare Biotechnology
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be... see more

Recent & Breaking News (NDAQ:INDP)

How Blockchain is Revolutionizing the Marijuana Industry

PR Newswire May 31, 2018

Canada's Cannabis Boom Could Be Taking Off Soon

PR Newswire May 18, 2018

Intec Pharma Reports First Quarter 2018 Financial Results and Corporate Update

PR Newswire May 15, 2018

Intec Pharma Presented Phase 1 PK and Safety Data From Accordion Pill Carbidopa/Levodopa at American Academy of Neurology Annual Meeting

PR Newswire April 24, 2018

Intec Pharma Announces Closing of $35.4 Million Public Offering of Ordinary Shares

PR Newswire April 13, 2018

Mid-Day Market Update: Analogic Falls Following Acquisition News; EyeGate Pharmaceuticals Shares Gain

Benzinga.com  April 11, 2018

Intec Pharma Announces Pricing of $35.4 Million Public Offering of Ordinary Shares

PR Newswire April 11, 2018

Intec Pharma Announces Proposed Public Offering of Ordinary Shares

PR Newswire April 10, 2018

Intec Pharma (Nasdaq: NTEC) to Ring The Nasdaq Stock Market Closing Bell

GlobeNewswire April 10, 2018

Intec Pharma Announces Poster Presentation at American Academy of Neurology Annual Meeting

PR Newswire April 4, 2018

Intec Pharma Ltd. to Host Key Opinion Leader Luncheon on Novel Drug Delivery Solutions in the Treatment of Parkinson's Disease

PR Newswire April 3, 2018

Intec Pharma Appoints Roger J. Pomerantz, M.D. to Board of Directors

PR Newswire March 26, 2018

Intec Pharma Reports Fourth Quarter and Year End 2017 Financial Results and Business Update

PR Newswire March 9, 2018

Intec Pharma, Ltd. to Present at Four Investor Conferences in March

PR Newswire March 5, 2018

Intec Pharma Names R. Michael Gendreau, M.D., Ph.D. as Chief Medical Officer

PR Newswire January 31, 2018

Intec Pharma Announces Development Collaboration With Global Pharmaceutical Company

PR Newswire January 8, 2018

Intec Pharma Granted Patent in Canada for Accordion Pill™ Carbidopa / Levodopa

PR Newswire January 3, 2018

Companies to Watch as Marijuana Approaches Legalization in Canada

PR Newswire December 22, 2017

Mid-Afternoon Market Update: Dow Surges 200 Points; SMART Global Shares Jump On Strong Guidance

Benzinga.com  November 16, 2017

Intec Pharma Reports Third Quarter 2017 Operating and Financial Results

PR Newswire November 15, 2017